Choose the right treatment for the right patients

Shwu-Jiuan Sheu^{1

2}

Affiliations

¹ Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
² Department of Ophthalmology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.

Editorial

Shwu-Jiuan Sheu. Taiwan J Ophthalmol. 2015 Oct-Dec.

. 2015 Oct-Dec;5(4):147-148.

doi: 10.1016/j.tjo.2015.10.001. Epub 2015 Dec 8.

Shwu-Jiuan Sheu^{1

2}

¹ Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
² Department of Ophthalmology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.

No abstract available

Conflict of interest statement

Conflicts of interest: The author declares no conflicts of interest.

1. Lux A, Llacer H, Heussen F, et al. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol. 2007;91:1318–1322. - PMC - PubMed
1. Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S. Non-re-sponders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol. 2013;97:1443–1446. - PubMed
1. Suzuki M, Nagai N, Izumi-Nagai K, et al. Predictive factors for non-response to intravitreal ranibuzumab treatment in age-related macular degeneration. Br J Ophthalmol. 2014;98:1186–1191. - PMC - PubMed
1. Schaal S, Kaplan H, Tezel T. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degenera tion. Ophthalmology? 2008;115:2199–2205. - PubMed
1. Martin DF, Maguire MG, Fine SL, et al. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–1398. - PMC - PubMed